Skip to main content




Pfizer submits initial data for COVID-19 vaccine booster authorisation

Pfizer submits initial data for COVID-19 vaccine booster authorisation

FILE PHOTO: A vial labelled with the Pfizer-BioNTech coronavirus disease (COVID-19) vaccine is seen in this illustration picture taken March 19, 2021. REUTERS/Dado Ruvic/Illustration/File Photo

WASHINGTON: Pfizer and its German partner BioNTech have submitted to US regulators the initial data from an early-stage trial toward seeking authorisation of a booster dose of their COVID-19 vaccine, the drugmakers said on Monday.

They said the third dose showed significantly higher neutralising antibodies against the initial SARS-CoV-2 virus compared to the two doses as well as against the Beta and the highly infectious Delta variants.

Pfizer has said its vaccine's efficacy drops over time, citing a study that showed 84 per cent effectiveness from a peak of 96% four months after a second dose. Some countries including Israel have already gone ahead with plans to give booster doses.

However, the decision by a few rich countries to buy booster shots has drawn the ire of health activists and the World Health Organization, which has called for a moratorium on boosters until at least the end of September.

Pfizer and BioNTech had said that all patients in the trial received the third shot, BNT162b2, eight to nine months after their second dose.

The drugmakers will submit the trial data to the European Medicines Agency and other regulatory authorities in the coming weeks. They said results from a late-stage trial of the third dose are expected shortly.

Last week, US regulators authorised a third dose of COVID-19 vaccines by Pfizer-BioNTech and Moderna for people with compromised immune systems who are likely to have weaker protection from the two-dose regimens.

BOOKMARK THIS: Our comprehensive coverage of the COVID-19 pandemic and its developments

Download our app or subscribe to our Telegram channel for the latest updates on the coronavirus outbreak:


Source: Reuters/ec


Also worth reading